methadone hydrochloride inn-farm 1 mg/ml roztwór doustny
inn-farm d.o.o., - methadoni hydrochloridum - roztwór doustny - 1 mg/ml
levomethadone hydrochloride molteni 2,5 mg/ml roztwór doustny
l.molteni & c. dei f.lii alitti societa di esercizio s.p.a. - levomethadoni hydrochloridum - roztwór doustny - 2,5 mg/ml
dutasteride + tamsulosin hydrochloride león farma 0,5 mg + 0,4 mg kapsułki twarde
laboratorios leon farma, s.a. - dutasteridum + tamsulosini hydrochloridum - kapsułki twarde - 0,5 mg + 0,4 mg
lidocaini hydrochloridum noridem 10 mg/ml roztwór do wstrzykiwań
noridem enterprises ltd. - lidocaini hydrochloridum - roztwór do wstrzykiwań - 10 mg/ml
lidocaini hydrochloridum noridem 20 mg/ml roztwór do wstrzykiwań
noridem enterprises ltd. - lidocaini hydrochloridum - roztwór do wstrzykiwań - 20 mg/ml
sitagliptin + metformin hydrochloride sandoz 50 mg + 1000 mg tabletki powlekane
sandoz gmbh - sitagliptini hydrochloridum monohydricum + metformini hydrochloridum - tabletki powlekane - 50 mg + 1000 mg
sitagliptin + metformin hydrochloride sandoz 50 mg + 850 mg tabletki powlekane
sandoz gmbh - sitagliptini hydrochloridum monohydricum + metformini hydrochloridum - tabletki powlekane - 50 mg + 850 mg
sitagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, type 2 - leki stosowane w cukrzycy - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. potrójnej terapii skojarzonej), jako uzupełnienie diety i ćwiczeń fizycznych u pacjentów niedostatecznie kontrolowanych o ich maksymalnej tolerowanej dawki sulfonylomocznika z metforminą i. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
sitagliptin + metformin hydrochloride grindeks 50 mg + 850 mg tabletki powlekane
as grindeks - sitagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 850 mg
sitagliptin + metformin hydrochloride grindeks 50 mg + 1000 mg tabletki powlekane
as grindeks - sitagliptinum + metformini hydrochloridum - tabletki powlekane - 50 mg + 1000 mg